Cover Image
市場調查報告書

歐盟5國的MA (醫療事務) 部門的評估:類風濕性關節炎

Medical Affairs Reputations (EU5): Rheumatoid Arthritis

出版商 FirstWord 商品編碼 351844
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
歐盟5國的MA (醫療事務) 部門的評估:類風濕性關節炎 Medical Affairs Reputations (EU5): Rheumatoid Arthritis
出版日期: 2015年11月01日 內容資訊: 英文
簡介

本報告以類風濕性關節炎治療藥的主要10個產品相關的醫療事務 (MA) 團隊上,歐盟5國的100名風濕症醫師為對象加以調查,彙整其對各公司團隊的效能及滿意度評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析。

對象的企業·品牌

  • AbbVie
    • Humira (Adalimumab)
  • Bristol-Myers Squibb
    • Orencia (abatacept)
  • Merck Sharpe & Dohme
    • Remicade (Infliximab)
    • Simponi (golimumab)
  • Mundipharma·Kern Pharma·Biogaran
    • Remsima (Infliximab)
  • Pfizer (原Hospira)
    • Enbrel (依那西普(Etanercept))
    • Inflectra (Infliximab)
  • Roche
    • MabThera (Rituximab)
    • RoActemra (tocilizumab)
  • UCB
    • Cimzia (certolizumab pegol)

調查課題

  • 各公司MA團隊對類風濕性關節炎的評估點
  • 互動的品質·效能·滿意度的個別分析·比較分析
  • 各公司MA團隊與類風濕性關節炎的互動:醫生的印象
  • 不足的資訊·必須改善的點
  • 醫生想與MA團隊取得聯繫的頻率
目錄
Product Code: 596200404

Is your rheumatoid arthritis Medical Affairs team leading the pack or following behind?

How well are the Medical Affairs teams from biosimilar manufacturers performing when compared with those from well-established products in the rheumatoid arthritis category? Has the need for education about biosimilars meant that teams are fully servicing physicians' information needs, or is there still room for improvement?

See where your EU5 Medical Affairs team comes in the latest ranking, together with insights into what services matter to physicians and where they would like further improvements.

Don't forget, if you also buy the US version you'll get a free comparison report, saving you time understanding and analysing the differences uncovered between these crucial markets.

Brands covered

  • AbbVie
    • Humira (adalimumab)
  • Bristol-Myers Squibb
    • Orencia (abatacept)
  • Merck Sharpe & Dohme
    • Remicade (infliximab)
    • Simponi (golimumab)
  • Mundipharma, Kern Pharma, Biogaran
    • Remsima (infliximab)
  • Pfizer (formerly Hospira)
    • Enbrel (etanercept)
    • Inflectra (infliximab)
  • Roche
    • MabThera (rituximab)
    • RoActemra (tocilizumab)
  • UCB
    • Cimzia (certolizumab pegol)

Top Takeaways

  • Close competition at the top of table: Two brands vie for top slot and have a significant margin compared with the rest
  • Report reveals the services physicians use: Physicians rank the services that they value the most so you can understand their essential requirements
  • All brands could increase satisfaction in at least one key area: Various information needs most frequently cited as needing improvement
  • Core needs are mostly met: Areas where physicians rely on Medical Affairs teams for help are awarded positive scores, even for the lower-ranking teams
  • Important needs of EU5 and US physicians vary: Differences are revealed in which services matter most to physicians. Get the comparison report free when you buy both the US and EU report.

Key issues explored

  • How physicians rate your rheumatoid arthritis Medical Affairs team using proprietary analysis and easy-to-understand visualisation tools, plus overall rankings
  • Interaction quality, performance and satisfaction measured and compared both overall and for each drug
  • How well physicians remember their interactions with your rheumatoid arthritis Medical Affairs team
  • Where do physicians think information for your brand is lacking? See outstanding information needs for your brand that will assist physicians in making decisions about competing treatments
  • How often physicians like to be contacted and the way they prefer to conduct their interactions with Medical Affairs teams
  • How the teams for new biosimilars rank against older, more established brands

Methodology

  • 150 rheumatologists evenly spread from the EU
  • Data was collected via a 15-minute internet-based questionnaire

Participants screened to ensure they:

  • See at least 5 patients for rheumatoid arthritis in a typical month
  • Have been in active practice between 3-35 years
  • Devote at least 50% of time to direct patient care
  • Have had an interaction with a Medical Affairs professional in the past 6 months for at least one of the listed products
Back to Top